Categories: BrainHealthcareNews

IRLAB to present at Pareto Securities’ Healthcare Conference in Stockholm on September 14, 2023

GOTHENBURG, SWEDEN / ACCESSWIRE / September 13, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 13, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will participate at Pareto Securities’ 14th Annual Healthcare Conference on Thursday, September 14, 2023, in Stockholm, Sweden.

Gunnar Olsson, CEO, will present the company at 15:50-16:10 CEST on September 14, 2023. This event is held at Hotel At Six, Brunkebergstorg 6, Stockholm in Studio 8.

Contact Pareto Securities’ for more information about the event.

For more information:

Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se

About IRLAB

IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinson’s disease. The company has its origin in Nobel Laureate Prof. Arvid Carlsson’s research group and the discovery of a connection between the brain’s neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed Phase IIb and is in preparation toward Phase III. Pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson’s disease. In addition, the company is also progressing the three preclinical programs IRL942, IRL757, and IRL1117 towards Phase I studies. The pipeline is driven by IRLAB’s proprietary systems biology-based Integrative Screening Process (ISP) research platform. Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.

Attachments

IRLAB to present at Pareto Securities’ Healthcare Conference in Stockholm on September 14, 2023

SOURCE: IRLAB Therapeutics

View source version on accesswire.com:
https://www.accesswire.com/783627/irlab-to-present-at-pareto-securities-healthcare-conference-in-stockholm-on-september-14-2023

Staff

Recent Posts

Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA (Euronext…

33 mins ago

Charting the Future of Nutrition: Mission Hill Foods Expands Research and Strengthens Market Presence in North America

Discover Mission Hill Foods' investment in advanced research, development, and sustainable practices for consumer health.CALIFORNIA…

4 hours ago

Leading the Future of Nutrition: Mission Hill Foods’ Innovations in Scientific Research and Sustainability

Exploring Mission Hill Foods' Pursuit of Excellence in Nutrition and Environmental ResponsibilityCALIFORNIA CITY, CA /…

4 hours ago

CardioComm Solutions Completes Debt Settlement

Toronto, Ontario--(Newsfile Corp. - July 10, 2024) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or…

8 hours ago

ProAssurance to Announce Second Quarter 2024 Results on Thursday, August 8, 2024

Investor call to be held at 10:30 a.m. ET on Friday, August 9BIRMINGHAM, Ala.--(BUSINESS WIRE)--ProAssurance…

9 hours ago

NuGen Announces Proposed Private Placement of up to $10 million Secured Convertible Debentures

Toronto, Ontario--(Newsfile Corp. - July 10, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…

10 hours ago